Ferrera A, et al. - Researchers assessed the performance of an HPV 16/18 E6 oncoprotein test, considering HPV encoded oncoproteins E6 and E7 are the main effectors of HPV carcinogenicity and are potential triage alternatives for cervical cancer screening in HPV positive women. This study was performed in a Honduran population with 155 women from a screening study and 59 from the same referral population attending colposcopy and with precancerous lesions. All participants had HPV-testing with HC2 and were genotyped with LiPA. For HPV16/18 E6 oncoproteins, cervical swabs were analyzed. Histologic HSIL was confirmed in 55 women; 31 (56.3%) were associated with HPV 16/18, 23 were associated with other types of HPV, and one was HPV negative. Using histologic HSIL/cancer as the gold standard, they assessed the sensitivity and specificity. For HPV16/18-related HSIL+ and for all HSIL+ regardless of HPV type, the estimated sensitivities were 96.8% and 56.4%, respectively. Specificity was 97.5%. Overall, the high sensitivity and high specificity of E6 oncoprotein as a marker for identifying HPV16/18-related HSIL lesions was seen in the studied population with limited previous screening. Furthermore, E6 oncoprotein could have utility as a triage method in screening programs, particularly in low income countries.